Patents Assigned to Ludwig-Maximilians-Universitat
-
Patent number: 12329990Abstract: A method and an apparatus for determining information regarding the location of energy deposition of an ion beam, in particular a proton beam, in an absorptive medium, such as in the tissue of a patient undergoing radiation therapy.Type: GrantFiled: February 28, 2023Date of Patent: June 17, 2025Assignees: Universität der Bundeswehr München, Technische Universität München, Ludwig-Maximilians-Universität MünchenInventors: Jannis Schauer, Günther Dollinger, Heinrich Ruser, Yuanhui Huang, Vasilis Ntziachristos, Hans Peter Wieser, Katia Parodi
-
Publication number: 20240336681Abstract: The present invention relates to an anti-CD47 antibody or an antigen-binding fragment thereof, comprising variable heavy chain complementarity determining regions 1 to 3 (CDRH1, CDRH2, CDRH3) and variable light chain complementarity determining regions 1 to 3 (CDRL1, CDRL2, CDRL3). The anti-CD47 antibody or an antigen-binding fragment thereof is capable of blocking the interaction of CD47 with signal regulatory protein alpha (SIRPalpha). Further envisaged is an anti-CD47 antibody or antigen-binding fragment combined to a further functional component.Type: ApplicationFiled: July 8, 2022Publication date: October 10, 2024Applicant: Ludwig-Maximilians-Universität MünchenInventors: Karl-Peter HOPFNER, Marion SUBKLEWE, Alexandra SCHELE, Nadja FENN, Enrico PERINI, Markus EISELE, Elisabeth KREMMER, Heinrich FLASWINKEL, Heinrich LEONHARDT
-
Publication number: 20240207414Abstract: The present application relates to a compound having the formula (I); A-L-B (I) wherein A is represented by; L is a bond or a self-immolative spacer; B is represented by; The compound is capable of releasing molecular cargo in the presence of a reductase and is thus suitable for treating, ameliorating, preventing or diagnosing a disorder selected from a neoplastic disorder; atherosclerosis; an autoimmune disorder; an inflammatory disease; a chronic inflammatory autoimmune disease; ischaemia; and reperfusion injury.Type: ApplicationFiled: March 22, 2022Publication date: June 27, 2024Applicant: Ludwig-Maximilians-Universitat MunchenInventors: Julia Thorn-Seshold, Jan Felber, Lukas Zeisel, Oliver Thorn-Seshold
-
Publication number: 20240156965Abstract: The present application relates to a compound having the formula (I) A-L-B wherein A is represented by (AA), L is a bond or a self-immolative spacer; and B is represented by (BB) or (CC). The compound is capable of releasing molecular cargo in the presence of a reductase and is thus suitable for diagnosing or quantifying the activity of the reductase and for treating, ameliorating, preventing or diagnosing a disorder selected from a neoplastic disorder; atherosclerosis; an autoimmune disorder; an inflammatory disease; a chronic inflammatory autoimmune disease; ischaemia; and reperfusion injury.Type: ApplicationFiled: April 7, 2022Publication date: May 16, 2024Applicant: Ludwig-Maximilians-Universitat MunchenInventors: Oliver Thorn-Seshold, Lukas Zeisel, Jan Felber
-
Patent number: 11827678Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.Type: GrantFiled: July 23, 2021Date of Patent: November 28, 2023Assignees: Amsilk GmbH, Ludwig-Maximilians-Universitat Munchen, Universitat BayreuthInventors: Lin Romer, Ute Slotta, Julia Engert, Gerhard Winter, Matthias Lucke, Thomas Scheibel
-
Patent number: 11667683Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.Type: GrantFiled: April 30, 2021Date of Patent: June 6, 2023Assignees: Amsilk GmbH, Ludwig-Maximilians-Universitat Munchen, Universitat BayreuthInventors: Lin Romer, Ute Slotta, Julia Engert, Gerhard Winter, Matthias Lucke, Thomas Scheibel
-
Publication number: 20220332737Abstract: The present invention relates to novel hydrolytically stable carbon-cyclic 5-aza-2-deoxycytidine and carbocyclic 5-aza-cytidine compounds and pro-drugs thereof as hypomethylating agents.Type: ApplicationFiled: June 5, 2019Publication date: October 20, 2022Applicant: Ludwig-Maximilians-Universität MünchenInventor: Thomas CARELL
-
Publication number: 20220296718Abstract: The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N—H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N?,N?-tetrakis-(2-hydroxyethyl) adipinic acid amide.Type: ApplicationFiled: July 10, 2020Publication date: September 22, 2022Applicants: Ludwig-Maximilians-Universität München, Danmarks Tekniske Universitet (DTU)Inventors: Gerhard WINTER, Andreas TOSSTORFF, Günther PETERS
-
Patent number: 11422094Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.Type: GrantFiled: January 11, 2019Date of Patent: August 23, 2022Assignees: Universiteit Hasselt, Ludwig-Maximilians-Universität MünchenInventors: Jelle Hendrix, Nick Smisdom, Don Lamb, Waldemar Schrimpf
-
Patent number: 11104708Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.Type: GrantFiled: June 13, 2017Date of Patent: August 31, 2021Assignees: Amsilk GmbH, Ludwig-Maximilians-Universitat Munchen, Universitat BayreuthInventors: Lin Romer, Ute Slotta, Julia Engert, Gerhard Winter, Matthias Lucke, Thomas Scheibel
-
Patent number: 10941200Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 24, 2017Date of Patent: March 9, 2021Assignees: Deutsches Zentrum Für Neurodegenerative Erkrankungen EV, Ludwig-Maximilians-Universität MünchenInventors: Christian Haass, Gernot Kleinberger, Kai Schlepckow
-
Patent number: 10851411Abstract: The present invention relates to methods of determining the sequence of nucleotides in target nucleic acid molecules. Thus, the invention relates to methods of sub-unit sequencing. The methods comprise the use of identification nucleic acid detection entities which specifically hybridize to the target nucleic acid, bind identification tags and have localization tags transiently bind thereto.Type: GrantFiled: February 6, 2017Date of Patent: December 1, 2020Assignees: Ludwig-Maximilians-Universität München, XGenomes Corp.Inventors: Johannes B. Wöhrstein, Kalim Mir, Ralf Jungmann, Florian Schüder
-
Publication number: 20200348234Abstract: The analysis of data from fluorescence microscopy is disclosed, more especially fluorescence fluctuation microscopy, being a correlation analysis of fluctuation of the fluorescence intensity enabling quantitative and dynamic information capture. In particular the analysis is described of characteristics such as concentrations, mobility, interactions, stoichiometry, etc. of mixtures of particular that are fluorescently labeled with differently colored fluorophores having different excitation/emission spectra using fluctuation microscopy.Type: ApplicationFiled: January 11, 2019Publication date: November 5, 2020Applicants: Universiteit Hasselt, Ludwig-Maximilians-Universität MünchenInventors: Jelle Hendrix, Nick Smisdom, Don Lamb, Waldemar Schrimpf
-
Publication number: 20200337279Abstract: This disclosure provides new animal models for studying Usher syndrome and developing new therapy. The technology is implemented in pigs, and other large animals in which the ophthalmic architecture and function more closely resembles architecture and function of the human eye. The animals have a genetic modification in which all or a portion of a human gene known to cause Usher syndrome in human patients replaces the host gene. Animals can be cloned or bred to be homozygous at the targeted locus, whereupon they manifest symptoms and signs of Usher syndrome. Since a substantial portion of the targeted gene has been humanized, the animals can be used to develop and test pharmacological agents such as gene therapy that are sequence dependent.Type: ApplicationFiled: April 27, 2020Publication date: October 29, 2020Applicants: Molecular Cell Biology, Ludwig-Maximilians-Universität München (LMU)Inventors: Uwe Wolfrum, Kerstin Nagel-Wolfrum, Nikolai Klymiuk, Eckhard Wolf
-
Patent number: 10441817Abstract: Disclosed is a method of determining information regarding the location of energy deposition of an ion beam, in particular a proton beam, in an absorptive medium, in particular in the tissue of a patient undergoing radiation therapy, comprising the following steps: generating an intensity modulated ion beam, wherein the intensity modulation comprises one or more modulation frequency components, detecting an acoustic signal attributable to the time dependent energy deposition in said absorptive medium by said intensity modulated ion beam using at least one detection apparatus, said detection apparatus being preferably configured for extracting at least one modulation frequency component of the acoustic signal corresponding to a respective one of the one or more modulation frequency components of said intensity modulation, or a harmonic thereof, and deriving information regarding the location of the energy deposition based, at least in part, on a time lag between the timing of the intensity modulation of saiType: GrantFiled: July 17, 2015Date of Patent: October 15, 2019Assignees: Ludwig-Maximilians-Universität München, Universität der Bundeswehr MünchenInventors: Günther Dollinger, Katia Parodi, Walter Assmann, Vasilis Ntziachristos, Stephan Kellnberger
-
Publication number: 20190185565Abstract: The present invention relates to a binding molecule having a binding site within the ectodomain of the triggering receptor expressed on myeloid cells 2 (TREM2), wherein the binding molecule inhibits TREM2 cleavage. Said binding molecule is particularly useful for treating and/or preventing a neurological disorder, such as a neurodegenerative disorder. Also encompassed by the present invention is a pharmaceutical composition for use in treating and/or preventing a neurological disorder, wherein the pharmaceutical composition comprises the binding molecule of the present invention. Neurodegenerative disorders that may be treated and/or prevented by using the binding molecule of the present invention include Alzheimer's disease (AD), Frontotemporal lobar degeneration (FTLD), FTLD-like syndrome, Parkinson's disease, Nasu-Hakola disease, Multiple sclerosis (MS), Huntington disease, immune-mediated neuropathies, or Amyotrophic lateral sclerosis (ALS).Type: ApplicationFiled: July 24, 2017Publication date: June 20, 2019Applicants: Deutsches Zentrum Fur Neurodegenerative Erkrankung EV, Ludwig-Maximilians-Universitat MunchenInventors: Christian Haass, Gernot Kleinberger, Kai Schlepckow
-
Patent number: 10295463Abstract: A method for investigating one or a plurality of phase objects is described, in which a grid made up of elements is used, which is illuminated with light of a light source, the coherence length of which is larger than the average spacing of adjacent elements of the grid. A diffraction image of the illuminating light scattered on the grid is generated, whereby the one or the plurality of phase objects are placed in the light path between the light source and the grid and/or in the light path of the illuminating light scattered on the grid. At least a part of the diffraction image is detected by an optical sensor directly or after interaction with further optical components and converted into a signal. The signal is analyzed further in order to ascertain information relating to the one or plurality of phase objects therefrom. A corresponding device is likewise described.Type: GrantFiled: November 12, 2014Date of Patent: May 21, 2019Assignee: Ludwig-Maximilians-Universität MünchenInventors: Philipp Paulitschke, Joachim Radler
-
Patent number: 9851303Abstract: Described is a system for inducing and detecting multi-photon processes, in particular multi-photon fluorescence or higher harmonic generation in a sample. The system comprises a dynamically-controllable light source, said dynamically-controllable light source comprising a first sub-light source, said first sub-light source being electrically controllable such as to generate controllable time-dependent intensity patterns of light having a first wavelength, and at least one optical amplifier, thereby allowing for active time-control of creation of multi-photon-excitation. The system further comprises a beam delivery unit for delivering light generated by said dynamically-controllable light source to a sample site, and a detector unit or detector assembly for detecting signals indicative of said multi-photon process, in particular multi-photon fluorescence signals or higher harmonics signals.Type: GrantFiled: June 3, 2015Date of Patent: December 26, 2017Assignee: Ludwig-Maximilians-Universität MünchenInventors: Robert Alexander Huber, Sebastian Karpf, Matthias Eibl
-
Patent number: 9784559Abstract: A swept source OCT system and related method are disclosed. The system comprises a control device for operating a tunable light source in response to an electronic sweep control signal such that the tunable light source carries out wave length sweeps with a repetition rate fsweep, which depends on the frequency of the sweep control signal. The system further comprises a detection device for the time-resolved detection of an interference signal from a sample beam and a reference beam with the help of a detection cycle signal. The sweep control signal and the detection cycle signal are phase-locked, or means for creating a signal or signal sequence are provided, said signal or signal sequence being characterising for the frequency relationship and/or the relative phase position of the sweep control signal and detection cycle signal.Type: GrantFiled: March 21, 2013Date of Patent: October 10, 2017Assignee: Ludwig-Maximilians-Universität MünchenInventors: Robert Alexander Huber, Thomas Klein, Wolfgang Wieser
-
Patent number: 9718811Abstract: The present invention relates to the (S)-enantiomer of mepazine, its applicability in therapy, a pharmacological composition comprising (S)-mepazine, and processes for the preparation of (S)-mepazine and one of its intermediates.Type: GrantFiled: June 25, 2014Date of Patent: August 1, 2017Assignees: Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ludwig-Maximilians—Universität MünchenInventors: Daniel Krappmann, Daniel Nagel, Florian Schlauderer, Katja Lammens, Karl-Peter Hopfner, Robert A. Chrusciel, Dale L. Kling